LATe TreatmENT Related Toxicity in Melanoma (LATENT)

To describe patterns of a range of medical late toxicities following immunotherapy treatment for advanced melanoma patients

Recent improvements in advanced melanoma treatment with immunotherapy have dramatically
 improved patient survival. Longer survival however has come at a cost of toxicity. Short term
 side effects can occur in 50% of patients undergoing immunotherapy treatment; however, many
 long-term survivors are also living with serious consequences of these treatments which may
 be under reported in literature.
 
 Data regarding long term toxicities, from these treatments is lacking and an area of
 important unmet clinical need. Therefore, in collaboration with the Clatterbridge and
 Christie's teams, the investigators propose to retrospectively analyse the nature, incidence,
 frequency, and severity of immune related toxicities in around 400 patients who received
 immunotherapy for advanced melanoma with ongoing durable responses to treatment of at least 3
 years.
 
 The investigators will set up a collective anonymized database and record this information
 through review of electronic medical records of patients that meet the eligibility criteria.
 The investigators will also review the patterns of use of long-term immunosuppression and
 assess the need for specialist referrals for managing late side effects.
 
 The investigators hope that this data will help us address gaps in the management of
 long-term survivors by identifying areas of need and establishing a coordinated evidence
 based multidisciplinary service to provide personalised, risk stratified long term follow up.